14-3-3 zeta as novel molecular target for cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 5, 2012, Pages 515-523

  Matta, Ajay ^a   Michael Siu, K W ^a   Ralhan, Ranju ^a,b,c,d  

^a YORK UNIVERSITY   (Canada)

^b Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

14 3 3 zeta; Cancer; Chemotherapy; Molecular target; Networks

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 14 3 3 ZETA PROTEIN; ANISOMYCIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; BCR ABL PROTEIN; BETA CATENIN; BV 02; CELL PROTEIN; CISPLATIN; DIFOPEIN; FLUOROURACIL; GUGGULSTERONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; R 18; RAF PROTEIN; RAPAMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STAUROSPORINE; TRANSCRIPTION FACTOR FKHRL1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CELL ADHESION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOPLASM; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HEAD AND NECK CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MULTIPLE CANCER; NONHUMAN; OVARY CARCINOMA; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA;

14-3-3 PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84860232887     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.668185     Document Type: Review

References (84)

1. Morrison DK. The 14-3-3 proteins: Integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19:16-23
2. Obsilova V, Silhan J, Boura E, et al. 14-3-3 proteins: A family of versatile molecular regulators. Physiol Res 2008;57:S11-S21
3. Muslin AJ, Xing H. 14-3-3 proteins: Regulation of subcellular localization by molecular interference. Cell Signal 2000;12:703-709
4. Tzivion G, Avruch J. 14-3-3 proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 2002;277:3061-3064
5. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-213
6. Neal CL, Yu D. 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010;14:1343-1354
7. Yang X, Lee WH, Sobott F, et al. Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc. Natl. Acad. Sci. USA 2006;103:17237-17242
8. Messaritou G, Grammenoudi S, Skoulakis EM. Dimerization is essential for 14-3-3zeta stability and function in vivo. J Biol Chem 2010;285:1692-1700
9. Gardino AK, Yaffe MB. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin. Cell Dev. Biol. 2011;22:688-695
10. Masters SC, Fu H. 14-3-3 proteins mediate an essential anti-Apoptotic signal. J Biol Chem 2001;276:45193-200
11. Masters SC, Subramanian RR, Truong A, et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans 2002;30:360-365
12. Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006;7:1
13. Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inactivation of the pro-Apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-49
14. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996;87:619-628
15. Yang H, Masters SC, Wang H, Fu H. The proapoptotic protein bad binds the amphipathic groove of 14-3-3zeta. Biochim Biophys Acta 2001;1547:313-319
16. Oh JE, Jang da H, Kim H, et al. Alpha3beta1 integrin promotes cell survival via multiple interactions between 14-3-3 isoforms and proapoptotic proteins. Exp Cell Res 2009;315:3187-3200
17. Chiang CW, Kanies C, Kim KW, et al. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol 2003;23:6350-6362
18. Macha MA, Matta A, Chauhan S, et al. 14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells. BMC Cancer 2010;10:655
19. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004;23:1889-1899
20. Ge F, Li WL, Bi LJ, et al. Identification of novel 14-3-3zeta interacting proteins by quantitative immunoprecipitation combined with knockdown (QUICK). J Proteome Res 2010;9:5848-5858
21. Matsuzawa A, Ichijo H. Molecular mechanisms of the decision between life and death: Regulation of apoptosis by apoptosis signal-regulating kinase 1. J Biochem 2001;130:1-8
22. Subramanian RR, Zhang H, Wang H, et al. Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14-3-3 proteins. Exp Cell Res 2004;294:581-591
23. Zhang L, Chen J, Fu H. Suppression of apoptosis signal-regulating kinase 1-induced cell death by 14-3-3 proteins. Proc. Natl. Acad. Sci. USA 1999;96:8511-8515
24. Zhou J, Shao Z, Kerkela R, et al. Serine 58 of 14-3-3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol 2009;29:4167-4176
25. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868
26. Gonfloni S. DNA damage stress response in germ cells: Role of c-Abl and clinical implications. Oncogene 2010;29:6193-6202
27. Yoshida K, Yamaguchi T, Natsume T, et al. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005;7:278-285
28. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006;16:183-192
29. Mils V, Baldin V, Goubin F, et al. Ducommun B. Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene 2000;19:1257-1265
30. Huang J, Manning BD. The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J 2008;412:179-190
31. Nellist M, Goedbloed MA, Halley DJ. Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins. Biochem Soc Trans 2003;31:587-591
32. Calvo F, Agudo-Ibanez L, Crespo P. The Ras-ERK pathway: Understanding site-specific signaling provides hope of new anti-Tumor therapies. Bioessays 2010;32:412-421
33. Petosa C, Masters SC, Bankston LA, et al. 14-3-3zeta binds a phosphorylated raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J Biol Chem 1998;273:16305-10
34. Van Der Hoeven PC, Van Der Wal JC, Ruurs P, et al. 14-3-3 isotypes facilitate coupling of protein kinase C-zeta to Raf-1: Negative regulation by 14-3-3 phosphorylation. Biochem J 2000;345:297-306
35. Neal CL, Xu J, Li P, et al. Overexpression of 14-3-3zeta in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2012;31:897-906
36. Oksvold MP, Huitfeldt HS, Langdon WY. Identification of 14-3-3zeta as an EGF receptor interacting protein. FEBS Lett 2004;569:207-210
37. Pozuelo-Rubio M. 14-3-3zeta binds class III phosphatidylinositol-3-kinase and inhibits autophagy. Autophagy 2011;7:240-242
38. Pozuelo-Rubio M. Regulation of autophagic activity by 14-3-3zeta proteins associated with class III phosphatidylinositol-3-kinase. Cell Death Differ 2011;18:479-492
39. Obsil T, Ghirlando R, Klein DC, et al. Crystal structure of the 14-3-3zeta: Serotonin N-Acetyltransferase complex, a role for scaffolding in enzyme regulation. Cell 2001;105:257-267
40. Liu D, Bienkowska J, Petosa C, et al. Crystal structure of the zeta isoform of the 14-3-3 protein. Nature 1995;376:191-194
41. Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 2010;24:1614-1619
42. Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010;70:2339-2349
43. Hengstschlager M, Rosner M, Fountoulakis M, Lubec G. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. Biochem Biophys Res Commun 2003;312:676-683
44. Ralhan R, Desouza LV, Matta A, et al. Discovery and verification of head-And-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008;7:1162-1173
45. Ralhan R, Desouza LV, Matta A, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009;8:300-309
46. Arora S, Matta A, Shukla NK, et al. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42:97-108
47. Sharma R, Samantaray S, Shukla NK, Ralhan R. Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 2003;81:481-488
48. Fan T, Li R, Todd NW, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007;67:7901-7906
49. Neal CL, Yao J, Yang W, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69:3425-3432
50. Yang X, Zhou J, Cao W, et al. 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 2011;2011:68-932-8
51. Chatterjee D, Goldman M, Braastad CD, et al. Reduction of 9-nitrocamptothecin-Triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int J Oncol 2004;25:503-509
52. Shen J, Person MD, Zhu J, et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004;64:9018-9026
53. Jang JS, Cho HY, Lee YJ, et al. The differential proteome profile of stomach cancer: Identification of the biomarker candidates. Oncol Res 2004;14:491-499
54. Matta A, Bahadur S, Duggal R, et al. Over-expression of 14-3-3zeta is an early event in oral cancer. BMC Cancer 2007;7:169
55. Matta A, DeSouza LV, Shukla NK, et al. Prognostic significance of head-And-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-Tandem mass spectrometry. J Proteome Res 2008;7:2078-2087
56. Lin M, Morrison CD, Jones S, et al. Copy number gain and oncogenic activity of YWHAZ/14-3-3zeta in head and neck squamous cell carcinoma. Int J Cancer 2009;125:603-611
57. Macha MA, Matta A, Sriram U, et al. Clinical significance of TC21 overexpression in oral cancer. J Oral Pathol Med 2010;39:477-485
58. Macha MA, Matta A, Kaur J, et al. Prognostic significance of nuclear pSTAT3 in oral cancer. Head Neck 2011;33:482-489
59. Sawhney M, Matta A, Macha MA, et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer 2009;124:2098-2105
60. Zang D, Li X, Zhang L. 14-3-3zeta overexpression and abnormal beta-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin Exp Med 2010;10:221-228
61. Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc. Natl. Acad. Sci. USA 2008;105:162-167
62. Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-218
63. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008;27:1315-1319
64. Lu J, Guo H, Treekitkarnmongkol W, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16:195-207
65. Wang Y. Breast cancer metastasis driven by ErbB2 and 14-3-3zeta: A division of labor. Cell Adhes Migr 2010;4:7-9
66. Danes CG, Wyszomierski SL, Lu J, et al. 14-3-3zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008;68:1760-1767
67. Hong HY, Jeon WK, Bae EJ, et al. 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Mol Cells 2010;29:305-309
68. Wang B, Yang H, Liu YC, et al. Isolation of high-Affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999;38:12499-504
69. Petosa C, Masters SC, Bankston LA, et al. 14-3-3zeta binds a phosphorylated raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J Biol Chem 1998;273:16305-10
70. Dong S, Kang S, Lonial S, et al. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 2008;22:572-577
71. Cao W, Yang X, Zhou J, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis 2010;15:230-241
72. Choi JE, Hur W, Jung CK, et al. Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett 2011;303:99-107
73. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005;170:295-304
74. Claerhout S, Decraene D, Van Laethem A, et al. AKT delays the early-Activated apoptotic pathway in UVB-irradiated keratinocytes via BAD translocation. J Invest Dermatol 2007;127:429-438
75. Corradi V, Mancini M, Manetti F, et al. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and imatinib-resistant leukemia cells to apoptosis. Bioorg Med Chem Lett 2010;20:6133-6137
76. Mancini M, Corradi V, Petta S, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther 2011;336:596-604
77. Matta A, DeSouza LV, Ralhan R, Siu KW. Small interfering RNA targeting 14-3-3zeta increases efficacy of chemotherapeutic agents in head and neck cancer cells. Mol Cancer Ther 2010;9:2676-2688
78. Maxwell SA, Li Z, Jaye D, et al. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284:22379-89
79. Qi W, Martinez JD. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res 2003;160:217-223
80. Bhat VB, Choi MH, Wishnok JS, Tannenbaum SR. Comparative plasma proteome analysis of lymphoma-bearing SJL mice. J Proteome Res 2005;4:1814-1825
81. Kobayashi R, Deavers M, Patenia R, et al. 14-3-3 zeta protein secreted by tumor associated monocytes/macrophages from ascites of epithelial ovarian cancer patients. Cancer Immunol Immunother 2009;58:247-258
82. He Y, Wu X, Liu X, et al. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. J Proteome Res 2010;9:6180-6190
83. Jiang F, Todd NW, Li R, et al. A panel of sputum-based genomic marker for early detection of lung cancer. Cancer Prev Res (Phila) 2010;3:1571-1578
84. Ralhan R, Masui O, Desouza LV, et al. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers. Proteomics 2011;11:2363-237